Eledon Pharmaceuticals (ELDN) Other Non-Current Liabilities (2015 - 2026)
Eledon Pharmaceuticals (ELDN) posted Other Non-Current Liabilities of $30.4 million for Q1 2026, up 166.1% on a QoQ basis from $11.4 million in Q4 2025, and down 12.72% year-over-year from $34.8 million in Q1 2025.
Eledon Pharmaceuticals (ELDN) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends
Eledon Pharmaceuticals' Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $30.4 million for Q1 2026.
- Quarterly Other Non-Current Liabilities fell 12.72% year-over-year to $30.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.4 million (down 12.72% YoY) and the FY2025 annual result came in at $11.4 million, down 74.55% from the prior year.
- Other Non-Current Liabilities was $30.4 million for Q1 2026 at Eledon Pharmaceuticals, up from $11.4 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $120.8 million in Q2 2024 and bottomed at $11.4 million in Q4 2025.
- A 4-year average of $49.0 million and a median of $39.8 million in 2024 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2024 — Other Non-Current Liabilities surged 115.06% — and 2025, when it slumped 81.37%.
- Eledon Pharmaceuticals' Other Non-Current Liabilities stood at $76.2 million in 2023, then tumbled by 41.13% to $44.9 million in 2024, then tumbled by 74.55% to $11.4 million in 2025, then jumped by 166.1% to $30.4 million in 2026.
- Business Quant data shows ELDN's Other Non-Current Liabilities at $30.4 million in Q1 2026, $11.4 million in Q4 2025, and $21.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,462.92 Bn | 67,462.64 Bn | - |
| 2 | Nanobiotix | 1,941.00 Bn | 1,940.94 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 473.07 Bn | 468.27 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.28 Bn | 116.03 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.12 Bn | 61.37 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.40 Bn | 62.40 Bn | - |
| 8 | Argenx Se | 56.45 Bn | 51.27 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Eledon Pharmaceuticals | 412.03 Mn | 412.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30.38 Mn |
| Dec 31, 2025 | 11.42 Mn |
| Sep 30, 2025 | 21.95 Mn |
| Jun 30, 2025 | 22.51 Mn |
| Mar 31, 2025 | 34.81 Mn |
| Dec 31, 2024 | 44.87 Mn |
| Sep 30, 2024 | 23.96 Mn |
| Jun 30, 2024 | 120.82 Mn |
| Mar 31, 2024 | 89.55 Mn |
| Dec 31, 2023 | 76.21 Mn |
| Sep 30, 2023 | 55.74 Mn |
| Jun 30, 2023 | 56.18 Mn |
| Dec 31, 2016 | 3.45 Mn |
| Mar 31, 2016 | 126,000.00 |
| Dec 31, 2015 | 88,000.00 |
| Sep 30, 2015 | 51,000.00 |
| Jun 30, 2015 | 13,000.00 |